**Beta Finch Podcast Script: Altria (MO) Q4 2025 Earnings**
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into tobacco giant Altria's fourth quarter 2025 results. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Thanks Alex. And wow, what a quarter for Altria. The company delivered some solid financials but also took a massive $1.3 billion impairment charge on their e-vapor business. That's not exactly chump change.
ALEX: Absolutely not. Let's start with the big picture numbers. Altria grew adjusted earnings per share by 4.4% for the full year and returned a whopping $8 billion to shareholders through dividends and share buybacks. That's serious cash returning to investors.
JORDAN: Right, and they're guiding for 2026 EPS between $5.56 and $5.72, which represents 2.5% to 5.5% growth. But here's the interesting part - CEO Billy Gifford said that growth will be "weighted to the second half of the year." That suggests a slower start to 2026.
ALEX: That timing issue ties into one of their big strategic moves. Altria is investing heavily in what they call "import-export capabilities" - basically a duty drawback program where they can manufacture cigarettes for international markets and then reimport them to get tax benefits. It's a complex play, but CFO Sal Mancuso said it has a payback period of less than a year.
JORDAN: That's actually pretty clever from a financial engineering standpoint. But let's talk about the elephant in the room - that $1.3 billion e-vapor impairment. They acquired NJOY to get into the vaping space, but the market is absolutely dominated by illegal flavored disposables from China.
ALEX: Exactly. Gifford said illegal products represent about 70% of the e-vapor category. Think about that - seven out of ten vaping products sold in the US are essentially operating outside FDA regulations. That makes it nearly impossible for legitimate companies like Altria to compete profitably.
JORDAN: But there might be a silver lining here. The company is seeing early signs that federal enforcement is starting to bite. Disposable e-vapor volume growth slowed from over 50% in 2024 to about 30% in 2025. Plus, Congress allocated at least $200 million in tobacco user fees specifically for enforcement activities.
ALEX: That enforcement angle is crucial for understanding Altria's strategy. They're basically saying "we'll wait on the sidelines until the government cleans up the illegal competition." Meanwhile, they're focusing on their nicotine pouch business, which is actually performing pretty well.
JORDAN: Speaking of nicotine pouches, their ON! brand is interesting. They got FDA authorization for ON! PLUS in December - that's their premium product with what they call "innovative pouch material and smooth flavor." They're positioning it as a premium option that can command higher prices than their classic ON! pouches.
ALEX: The numbers back that up. Helix, which makes the ON! products, shipped over 177 million cans for the full year, up about 11%. And while competitors were cutting prices - down 12% year-over-year according to Altria - they actually raised ON! prices by 3%.
JORDAN: But let's be real about the core business. Cigarette volumes declined 10% for the full year. That's a serious headwind. Even more concerning, Marlboro's retail share dropped below 40% for the first time ever.
ALEX: That Marlboro number caught my attention too. But Gifford pushed back on concerns during the Q&A, saying they're focused on "maximizing profitability over the long term" rather than chasing market share. They're also aggressively promoting their Basic discount brand in about 30,000 stores t
This episode includes AI-generated content.
続きを読む
一部表示
2026/02/221 分